Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms × darolutamide × Clear all

Phase

Status

Recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 9 Non-metastatic Castration-resistant Prostate Cancer 2 Prostate Cancer Non-Metastatic 1 Neoplasms 1 Metastatic Hormone-sensitive Prostate Cancer 1 Healthy Volunteers 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Breast Cancer Female 1 Biochemically Recurrent Prostate Cancer 1 Advanced Prostate Carcinoma 1

Interventions

Gemcitabine 84 Paclitaxel 75 Carboplatin 69 Bevacizumab 67 Surveys and Questionnaires 58 Docetaxel 58 pembrolizumab 57 Cisplatin 54 Exercise 41 Capecitabine 40 Cyclophosphamide 39 Sorafenib 36 Nivolumab 35 Fluorouracil 35 Irinotecan 33 Pemetrexed 32 Dexamethasone 30 Radiotherapy 28 Blood Specimen Collection 28 Erlotinib Hydrochloride 27 Oxaliplatin 26 Leucovorin 26 Cetuximab 24 Doxorubicin 23 130-nm albumin-bound paclitaxel 23 Sunitinib 22 Methods 22 Albumin-Bound Paclitaxel 22 Therapeutics 21 Standard of Care 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡